Published in Gastroenterology on June 01, 2001
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol (2012) 3.32
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology (2011) 2.33
Liver stem cells and hepatocellular carcinoma. Hepatology (2009) 2.27
Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol (2008) 2.24
Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19
The links between axin and carcinogenesis. J Clin Pathol (2005) 2.07
Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A (2004) 2.03
MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol (2009) 1.55
siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia (2007) 1.51
Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci (2011) 1.39
The way Wnt works: components and mechanism. Growth Factors (2012) 1.37
Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34
Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology (2009) 1.31
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest (2012) 1.24
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci (2011) 1.16
Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer (2010) 1.13
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One (2011) 1.12
Cancer stem cells and hepatocellular carcinoma. Cancer Biol Ther (2009) 1.11
Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology (2012) 1.10
Insulin-like growth factor-1 prevents miR-122 production in neighbouring cells to curtail its intercellular transfer to ensure proliferation of human hepatoma cells. Nucleic Acids Res (2014) 1.09
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev (2014) 1.07
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol (2006) 1.02
Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis (2010) 1.01
Chromosomal abnormalities determined by comparative genomic hybridization are helpful in the diagnosis of atypical hepatocellular neoplasms. Histopathology (2009) 1.01
Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma. Br J Cancer (2003) 1.00
Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol (2014) 0.98
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98
cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am J Pathol (2003) 0.94
Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology (2006) 0.94
Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol (2011) 0.94
Cancer stem cells: repair gone awry? J Oncol (2010) 0.92
Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl (2011) 0.90
The Wnt/β-catenin signaling pathway in liver biology and disease. Expert Rev Gastroenterol Hepatol (2010) 0.90
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer (2012) 0.89
Crosstalk between beta-catenin and snail in the induction of epithelial to mesenchymal transition in hepatocarcinoma: role of the ERK1/2 pathway. Int J Mol Sci (2013) 0.89
Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Oncogene (2015) 0.88
Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. J Hepatol (2006) 0.88
Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand. Hepat Res Treat (2011) 0.88
Molecular mechanisms underlying hepatocellular carcinoma. Viruses (2009) 0.87
Molecular pathogenesis of hepatic adenomas and its implications for surgical management. J Gastrointest Surg (2013) 0.86
S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS One (2013) 0.86
Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. PLoS One (2014) 0.86
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol (2015) 0.86
Identification of two Wnt-responsive elements in the intron of RING finger protein 43 (RNF43) gene. PLoS One (2014) 0.85
Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol (2005) 0.85
The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma. Chin J Cancer (2011) 0.85
Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci (2012) 0.85
Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol (2014) 0.85
Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int (2014) 0.84
Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol (2011) 0.84
Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish. PLoS Genet (2015) 0.84
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. Int J Cancer (2013) 0.83
Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics (2010) 0.83
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol (2012) 0.83
Expression of liver cancer associated gene HCCA3. World J Gastroenterol (2001) 0.83
Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol (2009) 0.83
Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One (2014) 0.82
Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: Report of a case. Surg Today (2011) 0.82
Identification of drivers from cancer genome diversity in hepatocellular carcinoma. Int J Mol Sci (2014) 0.81
A Complex Interplay between Wnt/β-Catenin Signalling and the Cell Cycle in the Adult Liver. Int J Hepatol (2012) 0.81
Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget (2015) 0.81
DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn (2014) 0.80
Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res (2011) 0.80
Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol (2009) 0.80
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol (2016) 0.80
Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma. World J Gastroenterol (2008) 0.79
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol (2007) 0.79
A peculiar mutation spectrum emerging from young peruvian patients with hepatocellular carcinoma. PLoS One (2014) 0.78
Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease. Cancer Med (2016) 0.78
Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. Mod Pathol (2016) 0.77
Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma. BMC Cancer (2014) 0.76
Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76
Aberrant regulation of Wnt signaling in hepatocellular carcinoma. World J Gastroenterol (2016) 0.76
β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. Mol Clin Oncol (2015) 0.76
Genomic losses at 5q13.2 and 8p23.1 in dysplastic hepatocytes are common events in hepatitis B virus-related hepatocellular carcinoma. Oncol Lett (2015) 0.76
Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear beta-catenin expression. Br J Cancer (2004) 0.76
Liver cell transformation in chronic HBV infection. Viruses (2009) 0.76
Dysregulation of GTPase IMAP family members in hepatocellular cancer. Mol Med Rep (2016) 0.75
Frizzled-7 promoter is highly active in tumors and promoter-driven Shiga-like toxin I inhibits hepatocellular carcinoma growth. Oncotarget (2015) 0.75
Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report. BMC Clin Pathol (2016) 0.75
Integrated Multiple "-omics" Data Reveal Subtypes of Hepatocellular Carcinoma. PLoS One (2016) 0.75
Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis (2016) 0.75
Investigation of chromosomal aberrations in Egyptian hepatocellular carcinoma patients by fluorescence in situ hybridization. Indian J Hum Genet (2010) 0.75
TP53/MicroRNA Interplay in Hepatocellular Carcinoma. Int J Mol Sci (2016) 0.75
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells. Oncotarget (2015) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Drosophila S6 kinase: a regulator of cell size. Science (1999) 6.76
Phosphorylation and activation of p70s6k by PDK1. Science (1998) 6.53
Mammalian TOR: a homeostatic ATP sensor. Science (2001) 6.41
CARD15 mutations in Blau syndrome. Nat Genet (2001) 5.79
Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J (1997) 5.57
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 5.34
Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol (2000) 5.26
Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature (1983) 5.14
Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J (1992) 5.05
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem (1992) 4.87
Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J (1994) 4.46
The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J (1995) 4.26
Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci U S A (1994) 4.16
Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev (2000) 4.05
Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res (1999) 4.04
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell (1998) 3.79
Activation of p70/p85 S6 kinase by a pathway independent of p21ras. Nature (1994) 3.67
Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature (2001) 3.65
Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol (1999) 3.50
Endoscopic ultrasound elastography: the first step towards virtual biopsy? Preliminary results in 49 patients. Endoscopy (2006) 3.44
Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) (2002) 3.33
Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol (1991) 3.29
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci U S A (1996) 3.09
Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science (2000) 3.07
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-beta-NGF in vivo. J Cell Biol (1990) 3.03
HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol (2000) 2.95
Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med (2001) 2.95
p70s6k function is essential for G1 progression. Nature (1993) 2.91
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
The modular phosphorylation and activation of p70s6k. FEBS Lett (1997) 2.85
beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 2.82
Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol (1996) 2.78
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med (1990) 2.73
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. Am J Transplant (2015) 2.71
The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol (1997) 2.66
The effect of serum, EGF, PGF2 alpha and insulin on S6 phosphorylation and the initiation of protein and DNA synthesis. Cell (1982) 2.63
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol (2000) 2.58
Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants. Am J Surg Pathol (1999) 2.53
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev (1999) 2.48
Genetics of hepatocellular tumors. Oncogene (2006) 2.43
Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem (1993) 2.40
Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J Biol Chem (1992) 2.38
Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med (1990) 2.36
Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol (1999) 2.33
Effect of adenotonsillectomy on nocturnal hypoxaemia, sleep disturbance, and symptoms in snoring children. Lancet (1990) 2.33
Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell (1993) 2.31
Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy (1993) 2.31
MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways. Nature (1991) 2.30
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet (1994) 2.28
alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A (1998) 2.28
The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol (1996) 2.28
Splenic and portal venous obstruction in chronic pancreatitis. A prospective longitudinal study of a medical-surgical series of 266 patients. Dig Dis Sci (1992) 2.26
PACS-1 binding to adaptors is required for acidic cluster motif-mediated protein traffic. EMBO J (2001) 2.26
Intracellular trafficking of furin is modulated by the phosphorylation state of a casein kinase II site in its cytoplasmic tail. EMBO J (1995) 2.22
Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology (2000) 2.21
Primary malignant melanoma of the esophagus: a case report and review of the literature. Dis Esophagus (2002) 2.20
Structure of a family of rat amylase genes. Nature (1980) 2.19
Association of p53 mutations with short survival in colorectal cancer. Gastroenterology (1994) 2.19
DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol (1994) 2.18
Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol (2001) 2.15
Randomized clinical trial of ischaemic preconditioning in major liver resection with intermittent Pringle manoeuvre. Br J Surg (2011) 2.15
Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet (1995) 2.13
BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J (1998) 2.11
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol (2010) 2.11
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09
Multiple phosphorylation of ribosomal protein S6 during transition of quiescent 3T3 cells into early G1, and cellular compartmentalization of the phosphate donor. Proc Natl Acad Sci U S A (1979) 2.09
Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem (1995) 2.08
Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J (1994) 2.06
Identification and characterization of a mitogen-activated S6 kinase. Proc Natl Acad Sci U S A (1988) 2.06
Origins of the CSF outbreak. Vet Rec (2000) 2.00
CompuCell, a multi-model framework for simulation of morphogenesis. Bioinformatics (2004) 1.97
Defective thymine dimer excision by cell-free extracts of xeroderma pigmentosum cells. Proc Natl Acad Sci U S A (1976) 1.97
Lysis of intravascular thrombus prior to coronary stenting using the dispatch infusion catheter. Cathet Cardiovasc Diagn (1996) 1.95
Direct measurement of the 7Be solar neutrino flux with 192 days of borexino data. Phys Rev Lett (2008) 1.93
Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Ann Surg (1999) 1.92
Mammalian subtilisin-related proteinases in cleavage activation of the paramyxovirus fusion glycoprotein: superiority of furin/PACE to PC2 or PC1/PC3. J Virol (1992) 1.91
The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. J Biol Chem (1993) 1.91
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
Kex2-like endoproteases PC2 and PC3 accurately cleave a model prohormone in mammalian cells: evidence for a common core of neuroendocrine processing enzymes. Proc Natl Acad Sci U S A (1991) 1.90
Phosphatidylinositol 3-kinase signals activate a selective subset of Rac/Rho-dependent effector pathways. Curr Biol (1996) 1.90
S6 kinase in quiescent Swiss mouse 3T3 cells is activated by phosphorylation in response to serum treatment. Proc Natl Acad Sci U S A (1988) 1.88
Protein phosphatase 2A inactivates the mitogen-stimulated S6 kinase from Swiss mouse 3T3 cells. J Biol Chem (1988) 1.87
Multiple genetic alterations in distal and proximal colorectal cancer. Lancet (1989) 1.87
Fine-needle aspiration cytology guided by endoscopic ultrasonography: results in 141 patients. Endoscopy (1995) 1.87